NCT02398591View on ClinicalTrials.gov

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ 53718678 in Healthy Japanese Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 1, 2015

Primary Completion Date

July 15, 2015

Study Completion Date

July 15, 2015

Conditions
Healthy
Interventions
DRUG

JNJ 53718678

JNJ 53718678 will be orally administered once in a dose of 250, 500 or 1000 mg on Day 1.

DRUG

Placebo

Placebo matching to JNJ 53718678 will be orally administered once on Day 1.

Trial Locations (1)

Unknown

Harrow

All Listed Sponsors
lead

Janssen Sciences Ireland UC

INDUSTRY

NCT02398591 - A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ 53718678 in Healthy Japanese Adult Participants | Biotech Hunter | Biotech Hunter